ECE2013 Poster Presentations Male reproduction (41 abstracts)
1Burghele Hospital, Bucharest, Romania; 2Societatea Civila Medicala Povernei, Bucharest, Romania.
Aim: To find if testosterone undecanoat 1000 mg injection (Nebido; Bayer-Schering) has a negative effect on prostate.
Materials and methods: i) PSA (ng/ml) was registred retrospective (from files) and prospective analysis (onset 2010). ii) From over 175 patients to whom testosterone undecanoate 1000 mg, i.m. was administrated at 3 months, in the last 4 years, and to whom the prostatic volume was quantified (Journal of Sexual Medicine8 suppl. 7, 2011: PO-05-013), 106 PSA analysis were done before treatment. PSA was recorded (if possible) at T1T7 (2 weeks4 years) (see Peretianu, this Congress); at least two analysis were registred. iii) None patient with prostatic cancer was included. iv) Statistical analysis: Students t-test, simple correlation, multiple regression.
Results: i) Patients: 106 men, 1896 years, average: 61.95; median: 62. ii) Prostatic volume (cm3): average: 37.89. iii) Average PSA: i) before treatment: 1.76; ii) post 1 year: 1.9; iii) post 2 years: 1.68; iv) post 3 years: 1.94; v) post 4 years: 2.18.
iv) Statistical difference of average: nonsignificant for all the times from 2 weeks to 4 years. v) Correlation between age and PSA is: i) significant before (r1) and after treatment after 2 years but nonsignificant for 3 and 4 years (PSA did not change as age after treatment). vi) Correlation between PSA and prostatic volume was significant, both before and after treatment.
vii) Multiple regression test (table) shows that PSA level post testosterone does not depend on testosterone but on age, prostatic volume (before and after treatment) and PSA initial level (before testosterone administration).
T0 | T12 weeks | T23 months | T36 months | T3 bis 9 months | T41 year | T52 years | T6 3 years | T74 years | |
Average | 1.76 | 2.87 | 2.45 | 2.81 | 2.20 | 1.90 | 1.68 | 1.94 | 2.18 |
S.D. | 1.68 | 3.06 | 2.54 | 3.38 | 3.11 | 1.78 | 1.36 | 1.70 | 2.20 |
No | 106 | 14 | 9 | 12 | 10 | 85 | 41 | 30 | 9 |
T value vs T0 | 0.20 | 0.44 | 0.31 | 0.67 | 0.59 | 0.76 | 0.61 | 0.59 |
Correlation age, PSA | Correlation prostatic volume, PSA | |||||||||
Before treatment | At 1 year | At 2 years | At 3 years | At 4 years | Before treatment | At 1 year | At 2 years | At 3 years | At 4 years | |
r | 0.34 | 0.33 | 0.31 | 0.15 | 0.07 | 0.60 | 0.49 | 0.55 | 0.42 | 1.00 |
P | <0.001 | <0.01 | 0.05 | >0.1 | >0.1 | <0.001 | <0.001 | <0.001 | <0.05 | <0.001 |
Observations | R2 | F | P | |
1 year TUD | 70 | 0.52 | 24.03 | <0.001 |
After 2 years TUD | 38 | 0.75 | 34.28 | <0.001 |
After 3 years TUD | 20 | 0.89 | 47.84 | <0.001 |
After 4 years TUD | 8 | 0.83 | 6.5 | 0.0509 |
Conclusions: i) Testosterone undecanoat 1000 mg injectable i.m. at 3 months does not increase significantly PSA level after 4 years administrations. ii) PSA level post testosterone is in fact dependent on age, prostatic volume before treatment and the level before treatment.